In VivoAnti-Tumor Activity of a New Doxorubicin Conjugateviaα-Linolenic Acid | Zendy

MengLei Huan | Zendy; Han Cui | Zendy; Zenghui Teng | Zendy; BangLe Zhang | Zendy; Jieping Wang | Zendy; Xinyou Liu | Zendy; Hui Xia | Zendy; Siyuan Zhou | Zendy; Qibing Mei | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In VivoAnti-Tumor Activity of a New Doxorubicin Conjugateviaα-Linolenic Acid

Author(s) -

MengLei Huan,

Han Cui,

Zenghui Teng,

BangLe Zhang,

Jieping Wang,

Xinyou Liu,

Hui Xia,

Siyuan Zhou,

Qibing Mei

Publication year - 2012

Publication title -

bioscience biotechnology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.509

H-Index - 116

eISSN - 1347-6947

pISSN - 0916-8451

DOI - 10.1271/bbb.120256

Subject(s) - doxorubicin , conjugate , in vivo , pharmacology , toxicity , moiety , chemistry , chemotherapy , medicine , cancer research , biology , stereochemistry , microbiology and biotechnology , mathematical analysis , mathematics

The conventional chemotherapy agent, doxorubicin, is of limited clinical use because of its systemic toxicity toward normal healthy tissue. A new doxorubicin conjugate with α-linolenic acid showed good anti-tumor activity with lower toxicity than free doxorubicin and exhibited an active tumor-targeting profile due to the introduction of α-linolenic acid which might be an effective tumor-targeting moiety for the modification of chemotherapeutics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research